Friday, January 07, 2022 11:58:13 AM
Scripts for week ending December 31, 2021 - New Year's Eve
Drug Industry TRx: -3.4% w/w
Vascepa
TRx 72,023; -3.1% (-2,291) w/w; -13.8% y/y
NRx 29,703; -11.9% (-4,012) w/w; -12.5% y/y
Ref 42,320; +4.2% (+1,721) w/w; -14.7% y/y
Lovaza (Generic & Brand)
TRx 57,625; -3.9% (-2,337) w/w; -6.4% y/y
NRx 26,719; -10.9% (-3,277) w/w; -7.4% y/y
Ref 30,906; +3.1% (+940) w/w; -5.6% y/y
Generic Vascepa
TRx 22,642; -6.2% (-1,501) w/w; As % of total V: 23.9%
NRx 12,088; -15.9% (-2,290) w/w; As % of total V: 28.9%
Ref 10,553; +8.1% (+789) w/w; As % of total V: 20.0%
Generic Vascepa by Manufacturer
Hikma - TRx 11,934 (-100); Generic share 52.7%; Total V share 12.6%
Reddy - TRx 10,704 (-1,405); Generic share 47.3%; Total V share 11.3%
Apotex - TRx 3 (+3); Generic share 0%; Total V share 0%
Vascepa + Generic Vascepa
TRx 94,664; -3.9% (-3,792) w/w; +8.3% y/y
NRx 41,791; -13.1% (-6,303) w/w; +16.8% y/y
Ref 52,873; +5.0% (+2,510) w/w; 2.5% y/y
Drug Industry TRx: -3.4% w/w
Vascepa
TRx 72,023; -3.1% (-2,291) w/w; -13.8% y/y
NRx 29,703; -11.9% (-4,012) w/w; -12.5% y/y
Ref 42,320; +4.2% (+1,721) w/w; -14.7% y/y
Lovaza (Generic & Brand)
TRx 57,625; -3.9% (-2,337) w/w; -6.4% y/y
NRx 26,719; -10.9% (-3,277) w/w; -7.4% y/y
Ref 30,906; +3.1% (+940) w/w; -5.6% y/y
Generic Vascepa
TRx 22,642; -6.2% (-1,501) w/w; As % of total V: 23.9%
NRx 12,088; -15.9% (-2,290) w/w; As % of total V: 28.9%
Ref 10,553; +8.1% (+789) w/w; As % of total V: 20.0%
Generic Vascepa by Manufacturer
Hikma - TRx 11,934 (-100); Generic share 52.7%; Total V share 12.6%
Reddy - TRx 10,704 (-1,405); Generic share 47.3%; Total V share 11.3%
Apotex - TRx 3 (+3); Generic share 0%; Total V share 0%
Vascepa + Generic Vascepa
TRx 94,664; -3.9% (-3,792) w/w; +8.3% y/y
NRx 41,791; -13.1% (-6,303) w/w; +16.8% y/y
Ref 52,873; +5.0% (+2,510) w/w; 2.5% y/y
Recent AMRN News
- Earnings Report Shows Narrowing Losses as Amarin (AMRN) Advances Partner-Led Growth Strategy • IH Market News • 04/29/2026 02:19:17 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/29/2026 11:06:34 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/29/2026 11:05:15 AM
- Amarin Reports 2026 First Quarter Financial Results • GlobeNewswire Inc. • 04/29/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:02 PM
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
